New combo therapy aims to control ovarian cancer and reduce painful fluid buildup

This study tests whether adding an experimental drug (APL-2) to standard immunotherapy (pembrolizumab) and/or a targeted therapy (bevacizumab) can better control recurrent ovarian, fallopian tube, or peritoneal cancer that causes fluid buildup in the belly or chest. About 60 adults with these cancers will be randomly assigned to one of three treatment groups. The goal is to see if the combinations reduce fluid accumulation and improve survival compared to bevacizumab alone.